Goldman Sachs’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-24,300
Closed -$247K 6788
2021
Q3
$247K Sell
24,300
-700
-3% -$7.05K ﹤0.01% 5612
2021
Q2
$250K Hold
25,000
﹤0.01% 5629
2021
Q1
$251K Buy
25,000
+1,700
+7% +$18.1K ﹤0.01% 5524
2020
Q4
$245K Buy
+23,300
New +$243K ﹤0.01% 4986

Other funds holding MTACU

Goldman Sachs's MTACU Position: Q4 2021 in Review

Goldman Sachs sold out of MedTech Acquisition Corporation Unit (MTACU) in Q4 2021, closing a stake of 24,300 shares — an estimated $247K sold.

Goldman Sachs first reported a position in MTACU in Q4 2020 and held it in 4 quarters. The position peaked at $251K in Q1 2021. 11 funds tracked by Wall St. Rank hold MTACU as of Q4 2021.

  • Goldman Sachs reported no remaining MedTech Acquisition Corporation Unit position as of Q4 2021 after selling out during the quarter.
  • Goldman Sachs sold 24,300 MedTech Acquisition Corporation Unit shares in Q4 2021, an estimated $247K.
  • Goldman Sachs first reported a position in MedTech Acquisition Corporation Unit in Q4 2020 and held it in 4 quarters.
  • Goldman Sachs's MedTech Acquisition Corporation Unit position peaked at $251K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.